Filter
30
Text search:
colchicine
Featured
8
6
Language
Document type
16
7
4
2
1
Countries / Regions
3
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
20
1
1
1
Toolboxes
12
6
2
1
1
Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended
This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up
...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi
...
WHO Model Formulary
recommended
For each medicine the Formulary provides information on use, dosage, adverse effects, contraindications and warnings, supplemented by guidance on selecting the right medicine for a range of conditions
16.7.2021
Updated Treatment Guidelines
Second Edition, 2012
6th edition
Solomon Islands pharmacy staff have developed an essential medicines supplies list. It was a collaborative effort involving a lot of staff taking the pictures and putting it all together. The list was launched as an initiative to improve the availability of medical stock within the country
6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.
NEMLIST | Sixth Edition | February 2016
16.7.2021
As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I
...
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for
...
